N7: evaluation of maximal chemotherapy dose intensity plus monoclonal antibody 3F8 in the treatment of neuroblastoma

Trial Profile

N7: evaluation of maximal chemotherapy dose intensity plus monoclonal antibody 3F8 in the treatment of neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Antineoplastics; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Monoclonal antibody 3F8 I-131; Vincristine
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Sep 2004) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top